CN101518547B - Ophthalmic preparation combination containing deproteinised calf blood extract - Google Patents
Ophthalmic preparation combination containing deproteinised calf blood extract Download PDFInfo
- Publication number
- CN101518547B CN101518547B CN 200810010480 CN200810010480A CN101518547B CN 101518547 B CN101518547 B CN 101518547B CN 200810010480 CN200810010480 CN 200810010480 CN 200810010480 A CN200810010480 A CN 200810010480A CN 101518547 B CN101518547 B CN 101518547B
- Authority
- CN
- China
- Prior art keywords
- calf blood
- gel
- blood protein
- removed extraction
- blood extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an ophthalmic preparation combination containing deproteinised calf blood extract, belonging to the field of medical preparation. The combination is used for restoring ocular tissue of traumatic, inflammatory and nutritional cornea and conjunctiva disease and contains deproteinised calf blood extract, gel matrix, pH regulator, antiseptic and thickener.
Description
Technical field
The present invention relates to a kind of calf blood protein-removed extraction preparation composition for eyes and preparation method of containing, belong to field of pharmaceutical preparations.
Background technology
Calf blood protein-removed extraction, it is a kind of biological preparation that German scholar professor Jaeger studies invention, be from newborn six months with interior healthy and grow the vigorous bovine blood, the molecular weight made from membrane filtration technique is less than 6000 Deproteinization blood extract.This deproteinize blood extract contains electrolyte, the indispensable element of trace and the intermediate product of nucleic acid derivative, aminoacid, oligosaccharide, low molecular polypeptide, glycolipid class and lipid metabolism etc.Calf blood protein-removed extraction can promote cell mitochondrial to picked-up and the utilization (not relying on insulin) of glucose and oxygen at cellular level, makes the synthetic increase of ATP, and cellular energy improves, and activates the plurality of enzymes vigor.In the situations such as low blood oxygen and energy need increase, improve rapidly the histiocyte anoxia state, improve microcirculation, activate the histiocyte hypertrophy, promote the reparation of damaged tissue cell, be a kind of high efficiency cell nutrient and prognosis.
Calf blood protein-removed extraction does not contain antigen, well-tolerated, and safety non-toxic, as a kind of medicine that promotes cellular energy metabolism, clinical effectiveness is good.The calf blood protein-removed extraction ophthalmic preparation mainly is applicable to traumatic, struvite and trophism cornea, conjunctive disorder, as: the corneal ulcer of various causes, corneal injury, by alkali or the sour ambustio corneae that causes, bullous keratitis, neuroparalytic keratitis, Cornea and conjunctiva degeneration; Also can be used for xerophthalmia.The crowd who suffers from this class ophthalmic is huge.At present, the new drug product that is used for the treatment of this type of disease that has gone on the market has: bFGF bovine basic fibroblast growth factor, recombinant human epidermal growth factor, be genetic engineered product, though the effect of the epidermal growth of promotion is arranged in theory, being situated between with needed enzyme in the actual body surface growth differs greatly, and just as Chinese herbal compounds effect is arranged, single extract may not have same purpose the same, still can not mention in the same breath with the calf blood extract.
The listing of calf blood protein-removed extraction ophthalmic preparation existing procucts.For example Switzerland's products that produce, commodity " Solcosery Eye Gel " by name are the eye ointment take calf blood protein-removed extraction as active component, and its repair in trauma to ocular tissue has obvious curative effect.
Although the research of calf blood protein-removed extraction ophthalmic preparation has become prior art, but at the therapeutic effect of product, the aspect such as medicine stability, bioavailability between the operating period, because the composition of drug prescription has larger difference, therefore the object of the present invention is to provide a kind of safe, effective, stay-in-grade calf blood protein-removed extraction preparation composition for eyes.
Summary of the invention
The present invention relates to the gel composition for eyes that a kind of ocular tissue for traumatic, struvite and trophism cornea, conjunctive disorder repairs, it contains calf blood protein-removed extraction, gel-type vehicle, pH adjusting agent.
In the gel composition for eyes of the present invention, contain by weight 10～30% calf blood protein-removed extraction.
Calf blood protein-removed extraction collection of the present invention calf of discontented 6 months after birth the technique such as is held back and obtains through removing albumen, inactivation of virus, ultrafiltration.The concrete requirement of calf blood protein-removed extraction that is applicable to compositions of the present invention is: protein content is below 0.1g/L; The breathing vigor of breathing decompression instrument mensuration Cavia porcellus liver pulp according to watt type micro should be not less than 2.0ulO2/mg.h; Free amino acid is contained in 0.4～3.0mg/ml, and content of peptides is no less than 0.5mg/ml.
The gel-type vehicle that is applicable to compositions of the present invention is selected from: card pool nurse, poloxamer, sodium carboxymethyl cellulose, hypromellose, chitosan and derivant thereof; Preferably carboxymethyl cellulose sodium.
Its pH scope of compositions of the present invention preferably remains on 6.0～8.0.Remain on 6.0～8.0 in order to keep pharmaceutical composition pH of the present invention, adoptable pH adjusting agent is selected from boric acid-Borax, sodium hydrogen phosphate, sodium hydrogen phosphate-sodium dihydrogen phosphate, boric acid-sodium carbonate and boric acid-sodium acetate.Preferably phosphate.
When the present composition selected sodium carboxymethyl cellulose to be gel-type vehicle, further optimizing its consumption (by weight percentage) was 0.5～3%.
When the present composition selected phosphate to be pH adjusting agent, further optimizing its consumption (by weight percentage) was 0.05～1%.
The present invention also can contain antiseptic.Preferred benzalkonium chloride, further optimizing its consumption (by weight percentage) is 0.005～0.02%.
The present invention also can contain thickening agent, can be selected from following one or more: polyvidone k
30, sorbitol, propylene glycol.
The present composition is selected polyvidone k
30During for thickening agent, further optimizing its consumption (by weight percentage) is 0.01～3%; When selecting sorbitol to be thickening agent, further optimize its consumption (by weight percentage) and be 1～5%, when selecting propylene glycol to be thickening agent, further optimizing its consumption (by weight percentage) is 0.05～3%.
The conventional preparation method of gel composition for eyes of the present invention: 1, gel-type vehicle used later on water-soluble swollen 12 hours; 2, drug component, pH adjusting agent, antiseptic, thickening agent with water dissolution after, add in the gel-type vehicle.
Embodiment
Concrete, the prescription that is applicable to gel composition for eyes of the present invention includes but not limited to following embodiment:
Embodiment 1
Contain calf blood protein-removed extraction 300g in per 1000 gram eye-gel preparations, sodium carboxymethyl cellulose 40g controls pH value 7.0 with boric acid-Borax as buffer salt, 0.05 of benzalkonium chloride, and surplus is pure water, is prepared into according to a conventional method gel for eye use.
Embodiment 2
Contain calf blood protein-removed extraction 100g in per 1000 gram eye-gel preparations, sodium carboxymethyl cellulose 30g, sodium dihydrogen phosphate 3g, benzalkonium chloride 0.2g, sorbitol 20g, propylene glycol 5g, surplus is pure water, is prepared into according to a conventional method gel for eye use.
Embodiment 3
Contain calf blood protein-removed extraction 140g in per 1000 gram eye-gel preparations, sodium carboxymethyl cellulose 5g, sodium hydrogen phosphate 2g, benzalkonium chloride 0.1g, sorbitol 40g, polyvidone 10g, surplus is pure water, is prepared into according to a conventional method gel for eye use.
Embodiment 4
Contain calf blood protein-removed extraction 200g in per 1000 gram eye-gel preparations, sodium carboxymethyl cellulose 20g, sodium hydrogen phosphate 2g, benzalkonium chloride 0.1g, propylene glycol 5g, surplus is pure water, is prepared into according to a conventional method gel for eye use.
Embodiment 5
Contain calf blood protein-removed extraction 200g in per 1000 gram eye-gel preparations, sodium carboxymethyl cellulose 20g, sodium hydrogen phosphate 2g, sorbitol 40g, polyvidone 10g, propylene glycol 5g, surplus is pure water, is prepared into according to a conventional method gel for eye use.
The present embodiment sample through the multicenter of Clinical efficacy and safety, at random, single blind studies show that: the corneal epithelial wound that the treatment of calf blood protein-removed extraction gel for eye use is caused by reasons such as wound, operations is effective, good safety is arranged, compare and have rapid-action advantage with the contrast medicine, after medication, more be better than contrasting medicine aspect the eye comfortableness.
Embodiment 6
Contain calf blood protein-removed extraction 240g in per 1000 gram eye-gel preparations, sodium carboxymethyl cellulose 25g, sodium hydrogen phosphate 2g, polyvidone 10g, propylene glycol 5g, surplus is pure water, is prepared into according to a conventional method gel for eye use.
Embodiment 7
Embodiment 4,5,6 samples place under 20～28 ℃, relative humidity 60% condition, carry out study on the stability (accelerating experiment).Place after 24 months, through check, breathing vigor, pH value, viscosity have no significant change, and prove in its operating period steady quality.
Claims (1)
1. an ophthalmic remedy compositions is characterized in that, said composition contains calf blood protein-removed extraction, gel-type vehicle, pH adjusting agent, antiseptic and thickening agent, it is characterized in that the content of each component in the said composition is by weight:
Calf blood protein-removed extraction 20%;
Sodium carboxymethyl cellulose 2%;
Sodium hydrogen phosphate 0.2%;
Benzalkonium chloride 0.01%;
Propylene glycol 0.5%;
Surplus is pure water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810010480 CN101518547B (en) | 2008-02-27 | 2008-02-27 | Ophthalmic preparation combination containing deproteinised calf blood extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810010480 CN101518547B (en) | 2008-02-27 | 2008-02-27 | Ophthalmic preparation combination containing deproteinised calf blood extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101518547A CN101518547A (en) | 2009-09-02 |
| CN101518547B true CN101518547B (en) | 2013-01-30 |
Family
ID=41079481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810010480 Active CN101518547B (en) | 2008-02-27 | 2008-02-27 | Ophthalmic preparation combination containing deproteinised calf blood extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101518547B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1586499A (en) * | 2004-07-08 | 2005-03-02 | 合肥兆峰科大药业有限公司 | Calf blood deproteinizing extract, its eye ointment preparation and its preparing method |
| CN1895275A (en) * | 2005-07-12 | 2007-01-17 | 锦州奥鸿药业有限责任公司 | Calf-blood deprotein extract gel |
-
2008
- 2008-02-27 CN CN 200810010480 patent/CN101518547B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1586499A (en) * | 2004-07-08 | 2005-03-02 | 合肥兆峰科大药业有限公司 | Calf blood deproteinizing extract, its eye ointment preparation and its preparing method |
| CN1895275A (en) * | 2005-07-12 | 2007-01-17 | 锦州奥鸿药业有限责任公司 | Calf-blood deprotein extract gel |
Non-Patent Citations (1)
| Title |
|---|
| 毕殿洲.外用凝胶剂，眼用制剂.《药剂学》.人民卫生出版社,2003,(第4版),381-382，278-279. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101518547A (en) | 2009-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101491498A (en) | aFGF liposome, preparation method and use thereof | |
| CN102357242B (en) | Recombination cattle alkaline fibroblast growth factor gel | |
| CN114425033B (en) | Eye gel containing mesenchymal stem cell exosomes and preparation method thereof | |
| CN104163847A (en) | Housefly larvae active protein peptide preparation method and housefly larvae active protein peptide prepared thereby and purpose of housefly larvae active protein peptide | |
| TW201000135A (en) | Pharmaceutical composition for treating xerophthalmia and/or disorder of cornea/conjunctiva | |
| CN113081956A (en) | Natamycin eye drops modified by oxidized sodium alginate and preparation method thereof | |
| CN106692949B (en) | Medicine for treating eye diseases and composition thereof | |
| ES2604471T3 (en) | Saccharide fraction from wheat, isolation procedure and field of use of the invention | |
| CN102100665B (en) | Eye drops containing vitamin E derivatives and preparation method thereof | |
| CN101780105B (en) | Eye drop of deproteinized calf blood extractive | |
| CN101518547B (en) | Ophthalmic preparation combination containing deproteinised calf blood extract | |
| CN105193837B (en) | A kind of creme and preparation method thereof of prevention and treatment joint disease | |
| CN102188695B (en) | Ophthalmic gel composition | |
| CN105920044A (en) | Hydra stem cell preparation as well as preparation method and application thereof | |
| CN100360141C (en) | Calf-blood deprotein extract gel | |
| EP2656853A1 (en) | Method for treating acute cerebral and spinal blood flow disorders of an ischaemic or haemorrhagic nature | |
| CN112957374A (en) | Dog serum deproteinized eye gel for dogs and preparation method thereof | |
| CN111588736A (en) | Artificial tear and preparation method thereof | |
| CN102302514B (en) | Pig blood deproteinized extract gel and preparation method thereof | |
| CN101337071B (en) | Composition for preparing anti-cataract products | |
| CN104546692A (en) | Recombinant calf alkaline fibroblast growth factor ophthalmic gel | |
| CN116726151B (en) | Daily throwing eye drops for cornea damage repair and preparation method thereof | |
| RU2726001C1 (en) | Aquaplant biologically active composition | |
| CN111000974B (en) | Rabbit milk active small peptide solution and extraction method and application thereof | |
| CN108245662A (en) | A kind of temperature sensitive type eye cyclosporin hydrogel and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 110027 Shenyang economic and Technological Development Zone, Liaoning, No. three, No. 12, No. 4, No. Applicant after: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. Address before: 110027 Shenyang economic and Technological Development Zone, Liaoning, No. three, No. 12, No. 4, No. Applicant before: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHENYANG XINGQI MEDICINE CO., LTD. TO: SHENYANG SINQI EYE PHARMACEUTICAL CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: No. 25 Xinyunhe Road, Shenyang Area, China (Liaoning) Pilot Free Trade Zone, Shenyang City, Liaoning Province, 110167 Patentee after: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. Address before: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, Shenyang, China Patentee before: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. |